EYPTEyePoint Pharmaceuticals, Inc.

Nasdaq eyepointpharma.com


$ 8.54 $ 0.27 (3.26 %)    

Thursday, 27-Jun-2024 14:35:20 EDT
QQQ $ 480.67 $ 0.69 (0.14 %)
DIA $ 390.47 $ -0.32 (-0.08 %)
SPY $ 544.77 $ -0.72 (-0.13 %)
TLT $ 93.59 $ 0.16 (0.17 %)
GLD $ 214.86 $ 0.15 (0.07 %)
$ 8.19
$ 8.27
$ 0.00 x 0
$ 0.00 x 0
$ 8.16 - $ 8.69
$ 5.67 - $ 30.99
644,564
na
433.36M
$ 1.25
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-08-2024 12-31-2023 10-K
3 11-03-2023 09-30-2023 10-Q
4 08-04-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 03-10-2023 12-31-2022 10-K
7 11-04-2022 09-30-2022 10-Q
8 08-05-2022 06-30-2022 10-Q
9 05-06-2022 03-31-2022 10-Q
10 03-12-2022 12-31-2021 10-K
11 11-05-2021 09-30-2021 10-Q
12 08-06-2021 06-30-2021 10-Q
13 05-05-2021 03-31-2021 10-Q
14 03-12-2021 12-31-2020 10-K
15 11-06-2020 09-30-2020 10-Q
16 08-05-2020 06-30-2020 10-Q
17 05-08-2020 03-31-2020 10-Q
18 03-16-2020 12-31-2019 10-K
19 11-07-2019 09-30-2019 10-Q
20 08-07-2019 06-30-2019 10-Q
21 05-10-2019 03-31-2019 10-Q
22 11-09-2018 09-30-2018 10-Q
23 09-18-2018 06-30-2018 10-K
24 05-10-2018 03-31-2018 10-Q
25 02-08-2018 12-31-2017 10-Q
26 11-08-2017 09-30-2017 10-Q
27 09-13-2017 06-30-2017 10-K
28 05-08-2017 03-31-2017 10-Q
29 02-09-2017 12-31-2016 10-Q
30 11-08-2016 09-30-2016 10-Q
31 09-13-2016 06-30-2016 10-K
32 05-06-2016 03-31-2016 10-Q
33 02-09-2016 12-31-2015 10-Q
34 11-06-2015 09-30-2015 10-Q
35 09-10-2015 06-30-2015 10-K
36 05-08-2015 03-31-2015 10-Q
37 02-06-2015 12-31-2014 10-Q
38 11-07-2014 09-30-2014 10-Q
39 09-11-2014 06-30-2014 10-K
40 05-14-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-eyepoint-pharmaceuticals-maintains-30-price-target

HC Wainwright & Co. analyst Yi Chen reiterates EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy and maintains $30 price...

 eyepoint-pharmaceuticals-to-highlight-duravyutm-clinical-and-regulatory-developments-at-rd-day-2024

– Phase 3 trial design for the LUGANO and LUCIA pivotal non-inferiority trials of DURAVYU in wet AMD based on positive EOP2 mee...

 cantor-fitzgerald-reiterates-overweight-on-eyepoint-pharmaceuticals

Cantor Fitzgerald analyst Jennifer Kim reiterates EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Overweight.

 jp-morgan-maintains-overweight-on-eyepoint-pharmaceuticals-lowers-price-target-to-32

JP Morgan analyst Tessa Romero maintains EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Overweight and lowers the price targe...

 hc-wainwright--co-maintains-buy-on-eyepoint-pharmaceuticals-lowers-price-target-to-30

HC Wainwright & Co. analyst Yi Chen maintains EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy and lowers the price tar...

 baird-maintains-outperform-on-eyepoint-pharmaceuticals-lowers-price-target-to-38

Baird maintains EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Outperform and lowers the price target from $46 to $38.

 chardan-capital-maintains-buy-on-eyepoint-pharmaceuticals-lowers-price-target-to-28

Chardan Capital analyst Daniil Gataulin maintains EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy and lowers the price tar...

 mizuho-maintains-buy-on-eyepoint-pharmaceuticals-lowers-price-target-to-30

Mizuho analyst Graig Suvannavejh maintains EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy and lowers the price target fro...